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Ras proteins are crucial players in differentiation and oncogenesis and thus constitute 
important drug targets. The localization and activity of Ras proteins are highly dependent 
on PTMs at their C-termini. In addition to an isoprenylated cysteine, H-Ras, but not other 
Ras proteins, possesses two cysteine residues (Cys181 and Cys184) in the C-terminal 
hypervariable domain that act as palmitoylation sites in cells. Therefore, the enzymes 
responsible for these modifications of H-Ras and the target residues are the subject 
of intense study as sites for therapeutic intervention. Here we describe the potential 
of several endogenous and exogenous small molecules to bind to a synthetic peptide 
from the hypervariable domain of H-Ras proteins. Cyclopentenone prostaglandins 
(cyPG) are reactive lipidic mediators that may bind covalently to proteins and activate 
H-Ras dependent pathways. Our results indicate that the dienone cyPG 15-deoxy-
Δ12,14-PGJ2 and Δ
12-PGJ2 can bind simultaneously Cys181 and Cys184 of H-Ras in 
vitro, thus possibly inducing important conformational changes of the hypervariable 
domain. In contrast, single enone cyPG bind the two cysteines independently, whereas 
cyclopentenone, which lacks the lateral chains of the PG, is a very poor modifier of this 
peptide and does not activate Ras-dependent pathways in cells. Interestingly, among 
several small molecules currently being tested, phenylarsine oxide, a widely used 
tyrosine phosphatase inhibitor, effectively binds H-Ras hypervariable domain. These 
observations open new perspectives for the study of molecules potentially modulating 
Ras-dependent pathways.
